Skip to content
TirzepatideReport

Tirzepatide monograph · Evidence review

MEDVi Tirzepatide Review: Cost, a Discontinued Product & Honest Verdict (2026)

An honest 2026 review of MEDVi tirzepatide — compounded tirzepatide is gone from the site, and the brand path hides its price.

Researched & written by Alan Pierce · last updated

Clinical Pharmacology Writer

FDA warning letter
FDA issued MEDVi, LLC dba MEDVi a warning letter in February 2026 (False & Misleading Claims/Misbranded (Telehealth)). Read the letter on FDA’s own warning-letter database.

On this page

Editorial pick

CoreAge Rx

$149/mo flat

Doctor-reviewed tirzepatide with one flat price and built-in human support.

Advertising disclosure · we may earn a commission at no extra cost to you.

Check availability
vs median
$120/mo below the $269 median
Market
$109–$429/mo across 396 providers
Dispensed
Compounded tirzepatide (503A)

Popular alternative

Shed (ShedRx)

Compounded tirzepatide from $239 with the widest set of formats here — injections, liquid drops, lozenges, and a real brand Zepbound pathway.

$299/mo

Check Shed (ShedRx) availability

MEDVi's compounded tirzepatide product is gone. This review's own live check of MEDVi's site found zero mentions of the word "tirzepatide" anywhere on the page, confirming prior research's finding that it has been removed from the site entirely. What remains is a brand-name path — Zepbound, which is itself tirzepatide under its FDA-approved name — priced as a $99/month membership with the medication cost billed separately and never published. Every fact here comes from the company's own published program.

What MEDVi is

MEDVi is a telehealth weight-loss platform, offering GLP-1 medication with clinical oversight through OpenLoop Health and CareGLP affiliated practices — both independently confirmed present in the site's own content. Its genuine strength is supply-chain transparency: it names four U.S. pharmacy partners, including Triad Rx — a level of disclosure most compounded providers skip entirely.

The word "tirzepatide" no longer appears on MEDVi's site

This review's own live check of glp.medvi.org searched for the word "tirzepatide" and found zero occurrences anywhere on the page — independently confirming prior research's finding that MEDVi's standalone compounded tirzepatide product has been removed from the site entirely. What remains is Zepbound — the FDA-approved brand name that itself contains tirzepatide as its active ingredient, so the molecule is still technically available here, just not sold under a standalone "compounded tirzepatide" listing or labeled with that word anywhere a reader would see it.

§ MEDVi — Compounded Tirzepatide Is Gone

ProductStatusPrice
Compounded tirzepatideDiscontinuedN/A — no longer offered
Brand ZepboundAvailable$99/mo membership + undisclosed drug cost
Independently: zero occurrences of the word 'tirzepatide' anywhere on MEDVi's site. Only the FDA-approved brand Zepbound path remains, with a $99/month membership and an undisclosed medication cost on top.

What MEDVi costs

MEDVi publishes a $99/month membership for its brand Zepbound path, but states the medication cost is charged on top without publishing it. That means there's no all-in figure to compare against a competitor's headline price — you'll need to complete intake to learn the real total.

The brand-vs-compounded question

Since compounded tirzepatide has been removed from MEDVi's site, the only route to the molecule here is brand Zepbound — the FDA-approved, trial-grade product. That's a genuine advantage in one sense: no compounded-vs-brand ambiguity to sort through. See our Zepbound cost and savings guide for the branded cash-price benchmark to compare against MEDVi's undisclosed drug cost.

How the care model holds up

MEDVi's real strengths: four named U.S. pharmacy partners (Triad Rx among them), clinical oversight through the established OpenLoop Health provider network, and both oral tablet and injectable formats on its semaglutide side. The trade-offs: no tirzepatide medication price is published at all — only the $99 membership, with the drug billed separately and undisclosed; compounded tirzepatide has been discontinued from the site entirely, confirmed independently by this review; MEDVi is not available in Mississippi or North Dakota, with five more states requiring a synchronous visit before prescribing; and no LegitScript or PCAB certification was disclosed. As with any GLP-1 program, get the real medication price before committing to the membership; tirzepatide carries labeled warnings for acute pancreatitis, gallbladder disease, and a boxed thyroid C-cell tumor warning — see our guides on Zepbound side effects, the gallbladder risk, and the thyroid cancer warning.

Does the drug work? (Separate from the provider)

Judge the provider on price, oversight and disclosure; judge the molecule on its trials. Tirzepatide's are strong — roughly 15–21% of body weight over 72 weeks in SURMOUNT-11, and better than semaglutide head-to-head2 — but they were run on the brand drug at FDA-approved doses. Our tirzepatide evidence guide has the full picture.

The honest verdict

MEDVi's compounded tirzepatide line is gone — this review independently confirmed the word doesn't appear anywhere on the site. What's left is a brand Zepbound path with a real membership fee and an undisclosed drug cost, making it hard to compare against providers that publish an all-in figure. If you want a provider still selling compounded tirzepatide with a published price, compare ShedRx or CoreAge Rx. See our best tirzepatide providers ranking for the full field.

Frequently asked questions

Does MEDVi still offer compounded tirzepatide?

No — this review's own live check found zero occurrences of the word 'tirzepatide' anywhere on MEDVi's site, independently confirming prior research's finding that the compounded product has been discontinued. Only the brand Zepbound path remains.

How much does MEDVi charge for its GLP-1 program?

MEDVi publishes a $99/month membership, but states the medication cost is charged on top without publishing what that figure is — you'll need to complete intake to see the real total.

Does MEDVi name its pharmacy partners?

Yes — four U.S. pharmacy partners are named, including Triad Rx, a level of disclosure most compounded providers in this category skip entirely.

References(2)

  1. Jastreboff AM, Aronne LJ, Ahmad NN, Wharton S, Connery L, Alves B, Kiyosue A, Zhang S, Liu B, Bunck MC, Stefanski A, and the SURMOUNT-1 Investigators (2022). Tirzepatide Once Weekly for the Treatment of Obesity.. New England Journal of Medicine. PMID: 35658024. https://pubmed.ncbi.nlm.nih.gov/35658024/
  2. Aronne LJ, Horn DB, le Roux CW, Ho W, Falcon BL, Bays HE, et al. (2025). Tirzepatide as Compared with Semaglutide for the Treatment of Obesity (SURMOUNT-5).. New England Journal of Medicine. PMID: 40353578. https://pubmed.ncbi.nlm.nih.gov/40353578/

About the author

Alan Pierce

Clinical Pharmacology Writer

About Tirzepatide Report · How we verify prices · This page last updated August 2026

Medical disclaimer: This content is for general educational purposes only and is not medical advice, diagnosis, or treatment. Always consult a licensed healthcare professional before starting, stopping, or changing any treatment.